Reading the tape
NASDAQ: SNDX
Syndax Pharmaceuticals, Inc.
Healthcare · Biotechnology
Market Cap
$1.90B
52w High
$25.59
52w Low
$8.58
P/E
-7.65
Volume
2.10M
Outstanding Shares
88.61M
Price vs Fundamentals
Why The Stock Is Moving
Fundamentals are supporting the moveModerate confidence
1Y Price: 95.19%Revenue (TTM): 396.72%FCF (TTM): 2.85%P/S: 18th pct
What changed
The stock rose 95.19% over the last year. Revenue grew 396.72% over the trailing twelve months. Operating margin moved from -786.59% to -102.93%. Free cash flow grew 2.85% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum, and the shares are still only around the 18th percentile of their historical P/S range.
What would invalidate this read
Operating margin is at -102.93%. Revenue grew 396.72% — this thesis depends on that trajectory holding. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Company profile
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer.
CEOMichael A. Metzger
SectorHealthcare
IndustryBiotechnology
Employees270
IPO dateMar 2, 2016
Valuation
Forward P/E—
EV/EBITDA-8.07
Enterprise value$2.03B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth223.64%
Gross margin97.96%▼0.58%vs FY2024
Operating margin-102.93%▲88.95%vs FY2024
ROE-441.62%▼299.18%vs FY2024
Analyst consensus
RatingBuy
Target price$41.50▲93.11%
20
Buy
2
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 3, 2026
Q3 FY26 · EPS est -$0.44 · Revenue est $80.65M
View